Disparities in the survival improvement of recurrent breast cancer
Disparities in the survival improvement of recurrent breast cancer
复制标题
DOI：
10.1007/s12282-009-0103-2
复制
发表时间：
2010-01-01
期刊：
影响因子：
4
通讯作者：
Toyoshima, Satoshi
中科院分区：
文献类型：
--
作者：
Anan, Keisei;Mitsuyama, Shoshu;Toyoshima, Satoshi
背景乳腺癌治疗的进步提高了早期疾病患者的生存率。然而，复发性疾病患者的生存改善仍然不明确。在这项回顾性研究中，我们检查了远处转移的复发性乳腺癌患者的生存改善是否存在差异。 方法 将 1990 年至 1996 年发生远处转移的 126 名患者的生存时间与 1997 年至 2003 年发生远处转移的 195 名患者的生存时间进行比较。 结果 与其他患者相比，在 1997 年至 2003 年期间发生复发的患者中观察到显着的生存改善。期间在 雌激素受体 (ER) 阳性疾病的亚群、接受辅助激素治疗的亚群以及无病间隔 (DFI) 为 24 个月或更长的亚群。然而，在每个对应者中都没有观察到显着的生存改善。 1997-2003年复发期ER阳性患者自首次复发起的中位生存时间（MST）比1990-1996年复发期长18.8个月（46.6个月对27.8个月）。 1997-2003年DFI≥24个月的患者MST比其他时间段长20.3个月(47.2个月vs 26.9个月)。结论复发乳腺癌的生存率有所改善,但存在差异。 ER 状态和 DFI 与患有远处转移的复发性乳腺癌女性的生存改善相关。
Background The therapeutic advances in breast cancer have improved the survival of patients with early disease; however, survival improvement of patients with recurrent disease remains ambiguous. In this retrospective study, we examined whether disparities in survival improvement exist in patients with recurrent breast cancer with distant metastasis.Methods The survival time of 126 patients who experienced recurrence at distant sites from 1990 through 1996 was compared to that of 195 patients who did from 1997 through 2003.Results A significant survival improvement was observed in the patients who experienced recurrence in the period of 1997-2003 in comparison to the other period in the subsets with estrogen receptor (ER)-positive disease, those who received adjuvant hormonal therapy, and those with a disease-free interval (DFI) of 24 months or more. However, no significant survival improvement was observed in each counterpart. The median survival time (MST) from the first relapse of patients with ER-positive disease in the recurrence period of 1997-2003 was 18.8 months longer than that in the recurrence period of 1990-1996 (46.6 months vs. 27.8 months). The MST of patients with a DFI of 24 months or more in 1997-2003 was 20.3 months longer than that in the other time period (47.2 months vs. 26.9 months).Conclusion The survival of recurrent breast cancer has improved with disparities. The ER status and the DFI are associated with a survival improvement of women with recurrent breast cancer with distant metastases.